Stockholm October 19th, 2021
BioLamina with partners in the innovation milieu IndiCell receive SEK 40M to establish and propel individualized cell therapy treatments in Sweden
The funded project focuses on an autologous therapy model, in which skin cells are harvested from the patients themselves, then carefully reprogrammed into induced pluripotent stem (iPS) cells in the laboratory, and finally returned to the patient as therapy.
The aspiring project will implement clinical workflows for stem cell therapy and will first focus on treatments for Parkinson’s Disease and Macular Degeneration. The long-term vision for the innovation milieu is to become a major center for supporting iPS cell-based treatments of various diseases in Sweden. The aim is to ensure that Swedish innovations within regenerative medicine can reach the clinical stage to benefit healthcare and patients.
“The gap between cell therapy research findings and commercial stage with clinical manufacturing is very difficult but important to close. IndiCell aims at setting the crucial processes and infrastructure for closing this gap and enabling the innovation projects and necessary competencies to stay within Sweden. BioLamina is part of building some of the core methodological processes and securing innovation management and further commercialization. We look forward to working with the fantastic team!”
Dr. Therese Kallur, Director Business Development at BioLamina
IndiCell consists of internationally leading academic scientists with experience in taking advanced cell therapies to the clinic (Lund Universitet, Karolinska Institutet, Kungliga Tekniska Högskolan), the public health care sector (Region Skåne, Region Stockholm), and life science companies (BioLamina AB, AcouSort AB, Lab-On-A-Bead AB). The innovation environment is coordinated by Lund University and led by Professor Anna Falk.
Cell therapy is the administration of live cells into a patient to replace damaged cells in the body. iPS cells enable a variety of cell replacement strategies since they have the potential to become any cell type of the human body. It is anticipated that during the coming 5-10 years period, engrafted cell therapies will significantly reduce the need for heavy drug treatments and will extend and enhance the life of patients.
The project is funded for 5-years by the Swedish Agency for Innovation, Vinnova. For more about the investment: Vinnova: Innovation environments for more accurate solutions in health
For more information, please contact:
Therése Kallur, Director Business Development
Press images: Photo gallery – BioLamina
BioLamina AB is a Swedish biotechnology company built on a scientific foundation with a legacy in matrix biology and cell culture-based research. Our flagship products, our biorelevant human recombinant laminin isoforms, Biolaminin®, are defined cell culture matrices that successfully imitate the natural, cell-specific cell-matrix interaction in the cell culture dish, allowing the cells to thrive and maintain their function. Our products are a powerful resource for scientists working with stem cells and primary cells both within basic research as well as in regenerative medicine companies with a focus on cell therapy applications.
We think you might be interested in…
Management Team Board Members Key shareholders Shareholder % of total shares outstanding Bure Growth
iPSC reprogramming and expansion
Reprogramming and expansion of human iPS cells on Biolaminin substrates High-efficiency iPSC re
Biorelevant culture of dopaminergic neurons on Biolaminin substrates Biolaminin culture supports GMP
Biorelevant culture of retinal cells on Biolaminin substrates Effective monolayer differentiati